Forte Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2018 - 2019
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2018 - 2019
Net Income	-43.71	-35.48	-31.48	-13.88	-21.71	-46.49	Upgrade
Depreciation & Amortization	0.04	0.04	0.01	-	0.04	0.05	Upgrade
Asset Writedown & Restructuring Costs	-	-	-	-	0.06	30.89	Upgrade
Loss (Gain) From Sale of Investments	-0.39	-0.16	-0.13	-	-	-	Upgrade
Stock-Based Compensation	3.91	3.1	3.28	4.01	4.21	0.96	Upgrade
Change in Accounts Payable	3.34	3.02	0.27	0.21	-0.29	-0.37	Upgrade
Change in Other Net Operating Assets	2.38	-1.26	-0.66	1.47	1.01	-3.46	Upgrade
Operating Cash Flow	-34.43	-30.75	-28.71	-8.19	-16.68	-18.42	Upgrade
Capital Expenditures	-0.09	-0.04	-0.09	-	-	-	Upgrade
Cash Acquisitions	-	-	-	-	-	3.58	Upgrade
Investment in Securities	0.39	-35.96	0.14	-	-	-	Upgrade
Investing Cash Flow	0.3	-35.99	0.05	-	-	3.58	Upgrade
Issuance of Common Stock	53.02	53.01	25.02	7.24	0.06	66.96	Upgrade
Repurchase of Common Stock	-0.03	-0.04	-0.06	-	-	-	Upgrade
Other Financing Activities	-3.44	-1.12	-0.27	-	-0.11	-0.29	Upgrade
Financing Cash Flow	49.54	51.86	24.68	7.24	-0.04	66.67	Upgrade
Net Cash Flow	15.41	-14.88	-3.98	-0.94	-16.72	51.83	Upgrade
Free Cash Flow	-34.53	-30.78	-28.79	-8.19	-16.68	-18.42	Upgrade
Free Cash Flow Per Share	-6.51	-10.56	-22.80	-11.77	-29.85	-62.59	Upgrade
Levered Free Cash Flow	-18.76	-16.14	-17.4	-3.18	-9.02	-8.1	Upgrade
Unlevered Free Cash Flow	-18.76	-16.14	-17.4	-3.18	-9.02	-8.1	Upgrade
Change in Working Capital	5.72	1.76	-0.39	1.68	0.72	-3.83	Upgrade

Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q